EClinicalMedicine
Intensive versus standard blood pressure control and overall brain small vessel disease burden: a post-hoc analysis of the SPRINT randomized clinical trial
Randomised trial in 663 peopleInterventions
3.9 years, dose-response, multicentre, registered NCT01206062, declared ties to: Astellas Pharmaceuticals, Elsevier, Biogen and 16 more
- Intensive systolic blood pressure control
- Hypertension
- Cerebral small vessel disease
- Global SVD factor
- Perivascular spaces
- Humans
The paper
Harvard University; The University of Texas at San Antonio Health Science Center
EClinicalMedicine, 11 Aug 2026
